• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Diabetes: Medtronic partners with Samsung, Glooko; wins 510(k) for MiniMed Connect

Diabetes: Medtronic partners with Samsung, Glooko; wins 510(k) for MiniMed Connect

June 5, 2015 By Fink Densford

medtronic-diabetes-1x1Medtronic (NYSE:MDT) today announced a slew of developments from its diabetes treatment arm, including FDA clearance of its MiniMed Connect diabetes monitoring system; a partnership with Samsung Electronics (LON:BC94) to develop technology for diabetes management; and an agreement with diabetes-monitoring platform developer Glooko. The announcements were made at the American Diabetes Assn.’s annual meeting in Boston.

The Fridley, Minn.-based medical device giant said it won 510(k) clearance from the FDA for its MiniMed Connect diabetes monitoring system. The system, slated for a fall release, consists of a small portable device, a smartphone app and a mobile or PC-based web display to track and view insulin pump and continuous glucose monitor data, the company said.

MiniMed Connect also allows remote monitoring, alarms if errors occur and text-based notifications for family or caretakers when glucose levels are too high or low, Medtronic said. The data is also collected for healthcare workers, who can use the it to adjust treatment plans for patients, the company added.

“Engagement from people with diabetes, loved ones and healthcare providers is key to living well with diabetes. With MiniMed Connect, the entire care team can have access to critical diabetes data to inform the decisions that help people have better outcomes. MiniMed Connect is another step in our broader strategy to be a holistic diabetes management company. The Connect platform represents how we will use leadership technologies, data and informatics to enable better therapy decision making and care for people with diabetes. Our hope is that this will make it easier for more people to manage their disease and optimize their therapy so they can achieve greater freedom and better health,” vice president of diabetes services and solutions Annette Brüls said in a prepared statement.

While the web-based remote monitoring will be available on any Internet-enabled device, the smartphone app will only be available initially on Apple (NSDQ:AAPL) iOS devices, Medtronic said.

Samsung will help Medtronic develop an app for Google (NSDQ:GOOG) Android devices that will be compatible with its MiniMed Connect as the first project of a new partnership with the Korean electronics maker.

The deal is slated to focus on developing a range of products for people with diabetes, from remote viewing of data to fully integrated mobile and wearable devices that operate with diabetes management systems, Medtronic said.

“By addressing more of the social and emotional aspects of living with diabetes and improving lifestyle fit, we believe that more people worldwide will be able to experience better diabetes control that today’s advanced therapies provide. Medtronic aims to transform diabetes by providing world-class integrated care, enabled by leading technologies, big data, and informatics. Our partnership with Samsung is a key step in providing convenient and discreet access to diabetes data, so together we can provide people with diabetes greater freedom and better health,” vice president and general manager of intensive insulin management Alejandro Galindo said in prepared remarks.

“Samsung is committed to applying its deep understanding of how people use technology to bring new innovations to healthcare. Patients are seeking better ways not only to monitor their condition, but also to enjoy a greater quality of life. We are excited to partner with Medtronic to develop diabetes management solutions that produce positive change and greater autonomy for people living with diabetes,” added Samsung Electronics America CMO Dr. David Rhew.

Medtronic also said it penned an agreement with Glooko to allow its cloud-based mobile diabetes management platform to incorporate information from Medtronic’s insulin pumps and CGMs. Other health data, such as food, medication, fitness and biometric data will be able to be incorporated through Medtronic’s CareLink platform, the company added. Glooko’s platform is designed to integrate data from more than 30 blood glucose monitors and other wearable and biometric devices with either an Apple iPhone or Google Android device. The company said yesterday that it has added Dexcom Inc. (NSDQ:DXCM) and Insulet (NSDQ:PODD) devices to its system, as well.

“Our goal is to provide people with diabetes, their care teams and healthcare providers with actionable insights that improve decision-making to optimize care. By partnering with  the Glooko diabetes management platform, we can provide safe and secure access to meaningful diabetes information to our customers that goes beyond just device data,” Brüls said in prepared remarks. “Combining the additional data collected by Glooko with our CareLink data will enable further insights into how various health and fitness activities affect insulin therapy. The Glooko partnership is part of our overall strategy to move towards a holistic diabetes management company and use our leading technologies, data and informatics to enable better therapy decision making and care for people with diabetes, to enable greater freedom and better health.”

“Medtronic customers and their healthcare teams can leverage the Glooko unified platform to improve outcomes and reduce costs by leveraging mobile and cloud based technology to better understand and act on insights to improve their care plan and lifestyle. Working together we will bring information from Medtronic insulin pumps and continuous glucose monitors, along with food, medication, fitness and biometric data, to offer a unified view and actionable insights to patients and their care teams,” added Glooko CEO Rick Altinger.

In March, Glooko closed a $16.5 million Series B round that included Medtronic, as well as Canaan Partners and existing backers The Social + Capital Partnership and Samsung.

Filed Under: Diabetes, Digital Health Tagged With: Alphabet (Google), Apple, Glooko, Medtronic, Samsung Electronics Co. Ltd.

More recent news

  • Pixee Medical reports first knee arthroplasty cases using its augmented reality nav tech
  • Alpheus Medical raises $52M for ultrasound-activated tumor therapy
  • Elucent Medical wins FDA breakthrough nod for in-body spatial intelligence system
  • EndoQuest Robotics completes first cases in pivotal surgical robot trial
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy